Heart BMJ

DECEMBER 13, 2024

Although significant secondary MR has been widely recognised for its adverse outcomes, moderate SMR has historically been considered a more benign entity. 3 Should we continue with a conservative, stepwise approach, beginning with pharmacological management and delaying intervention until MR severity worsens?

Pharmacology 52

Pharmacology Bicuspid/Mitral Heart Failure Outcomes 52

The British Journal of Cardiology

APRIL 2, 2025

Most services provided admission avoidance (96.5%), post-discharge checks (87%), pharmacological optimisation (99%), ongoing monitoring (82%) and palliative care (87%). Studies are needed to determine if they are adequately resourced to meet population needs and improve patient outcomes.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Nursing Pharmacology 40

Open Heart

NOVEMBER 17, 2022

Associations between pharmacological treatment and long-term survival were analysed using Cox proportional hazards models. Methods From Swedish medical registers, all patients diagnosed with AD in 2006–2015 were identified. Results Of 3951 patients hospitalised with acute AD, 3046 (77%) were discharged and alive at 30 days.

Pharmacology 52

Pharmacology Aortic Outcomes 52

Frontiers in Cardiovascular Medicine

JULY 24, 2024

This review delves into the current therapeutic strategies for CTEPH, including surgical pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), and targeted pharmacological treatments such as PDE5 inhibitors, endothelin receptor antagonists, sGC stimulators, and prostanoids.

Pulmonary 98

Pulmonary Hypertension Angioplasty Pharmacology 98

Circulation

FEBRUARY 9, 2025

On an equimolar basis, Lp(a) is ~5 to 6 times more atherogenic than particles that have been widely associated with adverse cardiovascular outcomes, such as LDL (low-density lipoprotein).

Pharmacology 49

Pharmacology Cardiovascular Disease Plaque Risk Factors 49

Frontiers in Cardiovascular Medicine

JUNE 3, 2024

Pharmacological therapy involves antiarrhythmic and anticoagulant drugs, though data are limited with potential adverse effects. Combining imaging techniques with electroanatomic navigation enhances outcomes. However, risk stratification for sudden death remains challenging due to anatomical variability.

Congenital Heart Disease 81

Congenital Heart Disease Congenital Heart Disease Arrhythmia 81

Circulation: Heart Failure

JANUARY 26, 2024

Circulation: Heart Failure, Ahead of Print.

Heart Failure 40

Heart Failure Pharmacology Obesity Outcomes 40

DAIC

FEBRUARY 27, 2024

The study will compare the safety and efficacy of the Laminar LAAX System to commercially available left atrial appendage (LAA) closure devices, providing a potential non-pharmacologic alternative for eligible patients.   The LAA, a potential source of clot formation, contributes to thromboembolic stroke in patients with NVAF. 

Atrial Fibrillation 105

Atrial Fibrillation Innovation AFIB Pharmacology 105

Journal of the American Heart Association

DECEMBER 1, 2023

The different outcomes of patients with DOAC failure were compared, including recurrent ischemic stroke, major cardiovascular events, intracranial hemorrhage and subarachnoid hemorrhage, mortality, and net composite outcomes according to switching to different DOACs or vitamin K antagonist after index ischemic stroke.

Atrial Fibrillation 75

Atrial Fibrillation Hemorrhage Pharmacology Stroke 75

Open Heart

JUNE 29, 2023

Primary outcomes included admission avoidance, readmission avoidance and patient satisfaction. Safety outcomes included unplanned discharge from the virtual ward, cardiovascular mortality and all-cause mortality. A rhythm control strategy was pursued in 82% (n=41) and 20% (n=10) required 3 or more remote pharmacological interventions.

Atrial Fibrillation 52

Atrial Fibrillation COVID-19 Atrial Flutter Blood Pressure 52

Journal of Clinical Investigation - Cardiology

SEPTEMBER 17, 2024

HSD3B1 encodes the rate-limiting enzyme for nongonadal androgen synthesis, 3β-hydroxysteroid dehydrogenase-1, and has a common adrenal-permissive missense-encoding variant that confers increased synthesis of potent androgens from nongonadal precursor steroids and poorer prostate cancer outcomes.METHODS Our prespecified hypothesis was that poor outcome (..)

Cancer 75

Cancer Pharmacology Physiology Outcomes 75

Heart BMJ

JUNE 25, 2024

The 91 villages underwent random allocation into two arms: the control arm, encompassing 45 clusters, was subjected to non-pharmacological intervention (educational training on healthy lifestyle), whereas the intervention arm, comprising 46 clusters, received the non-pharmacological interventions in conjunction with a once-daily polypill tablet.

Cardiovascular Disease 59

Cardiovascular Disease Myocardial Infarction Pharmacology Angina 59

Frontiers in Cardiovascular Medicine

AUGUST 6, 2024

Despite significantly improving atherogenic dyslipidaemia, the most recent clinical trial outcome has cast doubt on the utility of pharmacologically lowering triglyceride concentrations using fibrates. The outcome of these trials suggests alternate pathways involved in ASCVD risk modulation.

Cardiovascular Disease 52

Cardiovascular Disease Pharmacology Cholesterol Risk Factors 52

Hypertension Journal

JANUARY 11, 2024

While traditional therapeutic approaches to OH among patients with neurodegenerative disorders focus on increasing upright blood pressure to prevent cerebral hypoperfusion, the management of OH among patients with hypertension is more nuanced; resting hypertension is itself associated with adverse outcomes among these patients.

Hypertension 81

Hypertension Blood Pressure Pharmacology Research 81

International Journal of Cardiovascular Sciences

MARCH 13, 2023

Numerous pharmacological and non-pharmacological interventions have been developed to control and improve clinical outcomes, and all these aspects involve cardiometabolic diseases. In order to reduce this knowledge gap, IJCS launches this call for articles for this special issue entirely dedicated to cardiometabolism.

Pharmacology 52

Pharmacology Article Obesity Risk Factors 52

Open Heart

NOVEMBER 8, 2023

Background Currently, there is no head-to-head comparison of novel pharmacological treatments for heart failure with reduced ejection fraction (HFrEF).

Heart Failure 52

Heart Failure ACE Inhibitor Outcomes Pharmacology 52

Circulation

NOVEMBER 11, 2024

Background:In out-of-hospital cardiac arrest (OHCA) patients with an initial shockable rhythm, epinephrine increases the likelihood of return of spontaneous circulation (ROSC), but its effect on neurological outcome remains uncertain. 3.67], p=0.03). 1.37], p=0.39).Conclusion:In 1.37], p=0.39).Conclusion:In

Cardiac Arrest 40

Cardiac Arrest Hospital Outcomes Pharmacology 40

DAIC

APRIL 3, 2024

The “Pharmacology Program” will cover hot topics in cardiovascular medicine that are key issues that pharmacists, as well as other health care team members, face in managing complex patients. Advance health equity through education, advocacy and science.

Education 105

Education Preserved Ejection Fraction Coronary Artery Disease Cardio Oncology 105

Journal of Cardiovascular Pharmacology

OCTOBER 9, 2023

Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent one of the most important pharmacological innovations in the field of Cardiology of the last decades, having shown significant outcome improvement in all the heart failure (HF) spectrum. However, cost-effectiveness considerations should be made.

Heart Failure 40

Heart Failure Pharmacology Innovation Outcomes 40

Journal of the American Heart Association

MARCH 8, 2024

A slowly maturing evidence base has suggested that cardiogenic shock teams may improve patient outcomes.

Cardiogenic Shock 40

Cardiogenic Shock Best Practices Outcomes Education 40

Stroke Journal

JANUARY 30, 2025

Additionally, pharmacologically inhibiting Ripk2 is neuroprotective and reduces infarction and deficits after stroke. However, the impact ofRipk2deficiency on stroke outcomes in aged mice is unknown.

Stroke 40

Stroke Strokes Outcomes Pharmacology 40

Stroke Journal

JANUARY 30, 2025

This allows cells to survive longer in the hypoxic, low-glucose environment; however, long-term metabolic shift has been shown to inhibit the resolution of the inflammatory response and contribute to worsening outcomes in other cardio and neurovascular diseases.

Pharmacology 40

Pharmacology Stroke Strokes Outcomes 40

Stroke Journal

FEBRUARY 1, 2024

TCR activation was pharmacologically inhibited using the TCR-specific inhibitor AX-024, administered (10 mg/kg, i.p.) In the subsequent experiment, we explored the pathological implications of TCR activation on T cell activation, leukocyte brain infiltration, and neurological outcomes post-ICH.

Hemorrhage 40

Hemorrhage Outcomes Pharmacology Stroke 40

Frontiers in Cardiovascular Medicine

DECEMBER 13, 2023

Acupuncture, a core technique in the non-pharmacological treatment of Chinese medicine, plays an important role in the treatment of elevated blood pressure. The primary outcome was the efficiency rate of blood pressure reduction, and the secondary outcome was the change in blood pressure after treatment.

Hypertension 64

Hypertension Blood Pressure Public Health Pharmacology 64

Frontiers in Cardiovascular Medicine

JUNE 25, 2024

Inconclusive clinical outcomes of vitamin D supplements in cardiovascular diseases demonstrate the need to identify cause-effect relationships without bias. We employed a spectral clustering methodology capable of analyzing large diverse datasets for examining the role of vitamin D's genomic and non-genomic signaling in disease in this study.

Cardiovascular Disease 52

Cardiovascular Disease Genetic predisposition Pharmacology Cancer 52

Journal of Cardiovascular Electrophysiology

JANUARY 19, 2024

Objective This study aimed to compare the long-term follow-up outcomes of patients with severe cardioinhibitory syncope undergoing CNA with and without denervation confirmation via ECVS. Method A cohort of 48 patients, predominantly female (56.3%), suffering from recurrent syncope (5.1 ± 2.5

Outcomes 40

Outcomes Atrial Fibrillation Pharmacology Pacemaker 40

Frontiers in Cardiovascular Medicine

MARCH 4, 2024

There are numerous effective medications for modifying CAD but new pharmacologic therapies require increasingly large and expensive cardiovascular outcome trials to assess their potential impact on MACE and to obtain regulatory approval. For many disease areas, nearly a half of drugs are approved by the U.S.

Plaque 59

Plaque Coronary Artery Disease Blood Pressure Cardiovascular Disease 59

HeartRhythm

APRIL 30, 2024

Left atrial appendage occlusion (LAAO) has been widely adapted as a non-pharmacological alternative for thromboembolism prophylaxis in AF patients intolerant to chronic anticoagulation.

Pharmacology 40

Pharmacology Outcomes 40

DAIC

APRIL 11, 2024

Optimal medical therapy for coronary artery disease includes lifestyle modifications and intensive pharmacologic interventions, according to the contemporary guideline directed medical therapy for secondary prevention. Researchers also said that the observed rates of the primary outcome were lower than expected in both groups.

Plaque 111

Plaque Heart Attack Heart attacks Coronary Artery Disease 111

Frontiers in Cardiovascular Medicine

OCTOBER 15, 2024

Overall, 25 studies were found where BP was the primary outcome and discussed musical interventions within the US. Future EBI should target this underserved/high-burden group to improve disparity gaps within BP reduction via non-pharmacological means. However, based on the evidence, musical interventions are effective for BP reduction.

Blood Pressure 52

Blood Pressure Pharmacology Article Outcomes 52

Frontiers in Cardiovascular Medicine

DECEMBER 13, 2023

The secondary objectives were to determine the differences in HF functional class, pharmacological therapy and evaluate the prognostic value of MAGGIC Score in this population. group provided the worst outcome ( p  = 0.123). Most were male, average age 62.6 (56–70), 56–70), BMI 18.5–24.9 = 35.1%, Results BMI 30–34.9 and BMI 18.5–24.9

Outpatient 59

Outpatient Obesity Heart Failure BMI 59

Journal of Clinical Investigation - Cardiology

JUNE 3, 2024

Available behavioral and pharmacological treatments are supported by scientific evidence but are vastly underutilized. Discovery of additional medications, with a favorable balance of efficacy versus safety and tolerability can improve clinical uptake of treatment, allow personalized treatment, and improve outcomes.

Pharmacology 53

Pharmacology Outcomes 53

DAIC

MAY 16, 2024

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

Peripheral Arterial Disease 105

Peripheral Arterial Disease Exercise Ischemia Quality of Life 105

Frontiers in Cardiovascular Medicine

FEBRUARY 26, 2024

Graft selection has been shown to influence the outcomes following CABG. Composite grafting, pharmacological agents as well as latest minimal invasive techniques aim in the same direction. Coronary artery bypass grafting (CABG) is and continues to be the preferred revascularization strategy in patients with multivessel disease.

Coronary Artery Bypass Graft 59

Coronary Artery Bypass Graft Pharmacology Document Stents 59

Stroke Journal

MARCH 4, 2025

Genetic predispositions have been associated with post-subarachnoid hemorrhage cognitive outcomes and emphasize a role for personalized care strategies. Other rehabilitation strategies that enhance cognitive reserve and pharmacological interventions are discussed about improving the quality of life in survivors.

Hemorrhage 40

Hemorrhage Genetic predisposition Genetic Markers Quality of Life 40

Stroke Journal

JANUARY 30, 2025

However, heterogeneity was observed in studies assessing outcomes such as intraventricular hemorrhage and Glasgow Coma Scale (GCS), indicating variability in populations or methodologies.Conclusion:One of the significant life-threatening condicions is ICH, and patients are associated with poor prognosis.

Hemorrhage 40

Hemorrhage Pharmacology Hypertension Outcomes 40

Journal of Cardiovascular Pharmacology

SEPTEMBER 5, 2024

Heparin, the most utilized anticoagulant, carries concerns for heparin-induced thrombocytopenia and possible resistance given its dependence on co-factors and circulating proteins to exert its pharmacologic effect.

Laboratory 40

Laboratory Thrombosis Pharmacology Pulmonary 40